**Title : Nonmyeloablative matched sibling stem cell transplantation with** **optional reinforced stem cell infusion for patients with hemoglobinopathies**

Seung-Hwan Shin1, Sung-Soo Park2, Silvia Park2, Young-Woo Jeon3, Jae-Ho Yoon2, Seung-Ah Yahng 4, Byung-Sik Cho2, Yoo-Jin Kim2, Seok Lee2, Hee-Je Kim2, Chang-Ki Min2, Seok-Goo Cho2, Dong-Wook Kim2, Jong-Wook Lee2, and Ki-Seong Eom2

1Department of Hematology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea

2Catholic Hematology Hospital, Seoul St. Mary’s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea

3Department of Hematology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea

4Department of Hematology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea

**Running title:** Nonmyeloablative SCT for hemoglobinopathies

**Correspondence:** Ki-Seong Eom, M.D., Ph. D.

Catholic Hematology Hospital, Seoul St. Mary’s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, 06591 Banpo-daero 222, Seocho-gu, Seoul, South Korea

[dreom@catholic.ac.kr](mailto:dreom@catholic.ac.kr)

Phone: +82-2-2258-6056, Fax: +82-2-780-1283

**Abstract**

Nonmyeloablative (NMA)-conditioning stem cell transplantation (SCT) with alemtuzumab and low-dose total body irradiation (TBI) corrects the abnormal sickle cell disease (SCD) phenotype in the absence of graft-versus-host disease (GVHD). However, NMA regimens are rarely applied to patients with thalassemia major (TM). In this study, β-TM (N = 9) and SCD (N = 4) patients were equally effectively treated for eradicating the abnormal hemoglobin phenotype. However, to avoid prolonged immunosuppression after 1 year post-SCT, a two-stage strategy was developed, wherein a mixed donor chimerism was initially achieved using the protocol developed by the National Institute of Health (NIH), before facilitating donor chimerism using reinforced hematopoietic stem cell (SC) infusion in specific cases requiring protracted immunosuppression. A majority of the patients (N = 10), which include seven patients with β-TM, presented stable mixed chimerism (MC). Four out of the 5 reinforced infusion recipients achieved complete chimerism. An overall survival rate and event-free survival at 4 years of 91.7% (95% CI, 53.9–98.8) was achieved, with a thalassemia-free survival rate in β-TM patients of 87.5% (95% CI, 38.7–98.1). This study is the first to report successful NMA SCT to achieve stable MC and correct abnormal hemoglobin phenotype in adult patients with TM.

**Keywords:** Nonmyeloablative conditioning, sickle cell disease, thalassemia major

**1. INTROUDCTION**

Allogeneic stem cell transplantation (alloSCT) remains ~~only~~ a curative treatment option for various disorders, including malignant and non-malignant hematologic disorders. The rates of transplantation-related morbidity and mortality are often unacceptable, especially for patients with benign hematologic disorders, such as β-thalassemia major (β-TM) and sickle cell disease (SCD). Adult patients with these diseases, associated with both disease- and treatment-related organ complications, may be unable to tolerate alloSCT using conventional myeloablative (MAC) or reduced-intensity conditioning (RIC), resulting in significant transplantation-related morbidity and mortality. Therefore, alloSCT using non-myeloablative (NMA) conditioning can be considered as a feasible treatment option for these patients. However, earlier studies reported minimal toxicity after alloSCT using NMA regimen of low-dose total body irradiation (TBI) plus fludarabine in patients with β-TM and SCD patients, but resulted in only transient donor engraftment with consequent graft failure (GF) [1]. Recently, the National Institute of Health (NIH) developed the NMA regimen using alemtuzumab with low-dose TBI, whose application resulted in stable mixed-donor chimerism enough to the production of donor-type red blood cells and the reversion of the sickle cell phenotype. It also resulted in very low incidence of graft-versus-host disease (GVHD), which was associated with a low rate of treatment-related mortality (TRM) [2]. As for β-TM, because it has different biological and clinical features with SCD, including robust proliferation of bone marrow (BM) and allo-sensitization due to multiple transfusions, it is unclear whether this low-intensity conditioning is enough to overcome these features. Although conditioning with low-dose TBI plus alemtuzumab resulted in successful outcomes, the main population in previous studies were patients with SCD. In this setting, thalassemia-specific outcomes could not have been detailed so far.

In addition, a significant portion of the patients who received alloSCT using NMA conditioning with the NIH protocol were unable to cease immunosuppressive drug, because their donor T-cell chimerism did not reach 50% after one year, with a graft failure rate of 13% [2]. It is currently unclear how long patients who could not achieve a donor T-cell chimerism of over 50% should receive immunosuppression. Various complications due to protracted immunosuppressive drug administration should be a major concern. To address these issues, we have established a two-stage strategy; a mixed donor chimerism in alloSCT using NMA conditioning was initially achieved, followed by facilitating donor chimerism using optional reinforced hematopoietic stem cell (SC) infusion in cases requiring prolonged immunosuppression. Also, patients who experienced impending graft failure (GF) also received optional reinforced SC infusion. Herein, we will describe alloSCT using NMA conditioning with alemtuzumab and low-dose TBI, with the optional reinforced SC infusion for patients with β-TM and SCD.

**2. PATIENTS AND METHODS**

**2.1 Patients**

Patients (18 years or older) with an HLA-matched sibling donor (MSD) and hemoglobinopathies of **TM** and SCD were included in this study.

**2.2 Transplant-related procedures**

Similar to the NIH protocol, patients received a NMA conditioning regimen of alemtuzumab (Campath 1-H; 0.03 mg/kg for 1 day, 0.1 mg/kg for 1 day, then 0.3 mg/kg for 3 days; total dose 1.03 mg/kg on day –7 to –3) plus fractionated TBI (300–400 cGy for 1 day on day –2) [2]. Subsequently, peripheral blood (PB) stem cells (target CD34+ cell dose at least 10 × 106/kg) were mobilized with granulocyte-colony stimulating factor (G-CSF; 10 µg/kg filgrastim for 4 days) from MSD, and then administered to patients without manipulation. For the GVHD prophylaxis and maintaining sustained engraftment, all patients began to receive sirolimus loading at a dose of 15 mg/day starting day –1, then 5 mg/day after day 0, followed by dose adjustment of target trough level of 10–15 ng/ml for the first 3 to 4 months. Thereafter, we attempted to maintain a trough level of sirolimus to 5–10 ng/ml. After one year, we carefully tapered the sirolimus, if donor T-cell chimerism was maintained 50% or more in the absence of GVHD. If whole blood (WB) PB donor T-cell chimerism declined to <50% after one year or impeding GF was suspected, patients were administered optional reinforced infusion of SC from the same donors after total-nodal irradiation (TNI) at a single dose of 500 cGy. Informed consents were obtained from all patients. This study was approved by the Institutional Review Board of Seoul St. Mary’s Hospital.

**2.3 Definition of graft failure**

Primary GF was defined as lack of neutrophil engraftment (absolute neutrophil count <0.5×109/l) with a hypocellular marrow (aplasia) at day 28 or counts recovery with transfusion dependency (autologous recovery). Secondary GF was defined as when initial engraftment was followed by subsequent cytopenia [3]. Because we thought that patients who showed rapid decline of WB PB donor T-cell chimerism to 20% during the early post-transplant period have greater risk of overt GF, they were considered to have impending GF.

**2.4 Supportive care**

Antimicrobial prophylaxis with acyclovir and sulfamethoxazole-trimethoprim were administered to prevent herpes virus reactivation and pneumocystis jirovecii, respectively, combined with regular RQ-PCR monitoring for cytomegalovirus (CMV) DNA in the PB.

**2.5 Statistical analysis**

The primary outcomes of this study were event free survival (EFS) and overall survival (OS). The EFS was calculated from the date of transplantation to the any occurrence of an event or last follow-up. Event was defined as primary and secondary GF or any cause of death, patients being censored if they were alive without event. The OS was calculated from the date of transplantation to any cause of death or last follow-up, patients being censored if they were alive. In addition, any requirement for a red cell transfusion or failure to achieve thalassemia-free disease status was defined as a β-TM-specific event. An SCD-specific event was defined as a clinical manifestation of SCD or a failure to achieve donor-type hemoglobin S (HbS).

**3. RESULTS**

**3.1 Patient demographics and disease-related characteristics**

Between April 2014 and March 2019, 13 consecutive adult patients of Arabid ethnicity were included in this analysis (Table 1). They consisted of 6 (46.2%) male and 7 (53.8%) female with a median age of 31 (range, 24–34) years at transplantation. The proportion of female donor to male recipient pairs was 15.4% (95% CI, 1.9–45.4). Major and minor ABO mismatches transplantations between the donor and recipient were included (n = 3 in both). All patients were afflicted with hemoglobinopathies, including β-TM in 9 (69.2%) and SCD in 4 (30.8%). A patient with β-TM (UPN #01), who was referred after experiencing GF with previous MAC transplantation from another hospital, was included in our cohort. More detailed patient demographics and disease-related characteristics are described in Table 1.

**3.2 Major transplant-related outcomes**

The overall outcomes are summarized in Fig. 1 and Table 2. All patients received an initial PB SC infusion of median CD34+ cells of 14.6 × 106/kg (range, 8.8–33.3) and CD3+ cells of 55.1 × 107/kg (range, 15.8–77.3) after NMA conditioning. One (7.7%) and four (30.8%) patients did not experience neutrophil (<0.5 × 109/L) or platelet (<50 × 109/L) nadirs, respectively. The remaining patients achieved neutrophil and platelet engraftments at a median of 14.5 days (range, 12–21) and 14 days (range, 12–25), respectively. The cumulative incidences of neutrophil and platelet engraftments at day 28 were 100% for both. The median PB donor’s T-cell chimerism at 1 month was 84% (range, 3–97). There were two patients (one with TM and one with SCD) who showed rapid decline of donor chimerism in their WB to 20% (22% and 33%, respectively) during the early posttransplant period, with occasional transfusion requirement from 1.9 months and 6.2 months post-transplant, respectively.

**3.2.1 β-thalassemia major**

There were 9 β-**TM** patients. One of them was ineligible for weaning from ISM, because the patient was under 1 year posttransplant at the time of data collection. Of the remaining 8 patients, 1 (UPN #10) had impending GF with occasional red cell transfusion requirement. The other 7 patients had stable mixed chimerism (MC). However, three of them failed to achieve sustained donor T-cell chimerism (more than 50%) after 1 year post-transplant and one refused the reinforced infusion and is currently taking ISM at 22.8 months post-transplant. Including the patient with impending GF, a total of three received the reinforced SC infusion each at 3.9, 15.1, and 37.6 months posttransplant, respectively. Of the 7 patients with stable MC, four showed sustained donor T-cell chimerism (more than 50% after 1 year post-transplant) and discontinued sirolimus each at 13.2, 14.1, 14.7 and 16.5 months post-transplant, respectively. Currently, all four maintain to be stable MC. The mean hemoglobin levels increased after SCT. The mean hemoglobin levels for women before HSCT were 8.0 g/dL (range, 7.4–9.5) vs 11.0 g/dL (range, 10.0–13.0) after SCT (at the most recent follow-up). For men, they were 8.0 g/dL (range, 7.4–9.2) before SCT vs 11.0 g/dL (range, 9.0–13.7) after HSCT. To date, no patients have required red cell transfusion regardless of the need for reinforced SC infusion or have required hospitalization. A genetic study revealed that all initial genetic abnormalities were corrected to donor-type genes, even before reinforced SC infusion.

**3.2.2. Sickle cell disease**

Of the 4 patients with SCD, the one with impending GF underwent reinforced infusion at 7.2 months post-transplant. The remaining 3 achieved stable MC; 2 of them showed persistently low donor T-cell chimerism after 1 year post-transplant. Of the 2, one of them refused reinforced infusion and continued ISM (WB and T-cell chimerism of 83% and 43%, respectively, at 27.3 months post-transplant). The other patient underwent reinforced infusion at 20.7 months post-transplant. The last patient with stable MC and sustained donor T-cell more than 50% after 1 year post-transplant (UPN #6) discontinued sirolimus at 18.4 months. The mean hemoglobin level improved in the patients; from median 6.0 g/dL to 13.5 g/dL in male patients, and from 7.5 g/dL to 11.5 g/dL in female patients. The recipients achieved the same percentage of HbS as their donors after SCT; from median 72.9% to 37.4% (most recent). No patients with SCD suffered disease-related complications and all patients achieved donor type HbS. Only 1 patient was hospitalized due to non-specific colitis. All genetic defects were also replaced by donor-type, regardless of the administration of reinforced SC infusion.

**3.3 Graft-versus-host disease, complications, and survival**

Before receiving reinforced SC infusions, none of the patients had developed acute and chronic GVHD. Infectious complications of grade 3 was observed in one (7.7%). CMV reactivation requiring pre-emptive therapy, CMV disease, sinusoidal obstruction syndrome, and herpes zoster were not observed in any patients.

Seven patients (53.8%) showed requirements for reinforced SC infusion (β-**TM**, N = 4; SCD, N = 3), including failure to achieve donor T-cell chimerism over 50% after 1 year and thereafter (N = 5) and impending GF (N = 2). Five patients proceeded to reinforced SC infusion at a median of 15.1 months (range, 3.9–37.6), with a median PB donor T-cell chimerism of 30.0% (range, 17.0–40.0). The median infusion of CD34+ and CD3+ cells was 10.7 × 106/kg (range, 8.5–14.4) and 24.7 × 107/kg (range, 16.3–52.9), respectively. No neutrophil or platelet nadirs were observed. Two patients did not receive reinforced SC infusion due to patient refusal. Of the 5 patients who underwent reinforced SC infusion, 1 patient (UPN #11) developed severe acute gut GVHD, which was refractory to corticosteroid, and subsequently died of pneumonia complicating adult respiratory distress syndrome 1 month after infusion. The number of CD34+ and CD3+ cells at the reinforced infusion was 8.5 × 106/kg and 52.9 × 107/kg, respectively, the highest amounts for all reinforced infusion recipients. One other patient (UPN #2) developed chronic oral GVHD, which was partially responsive to corticosteroid, and was subsequently administered ruxolitinib for 5 months. Currently, this patient discontinued ruxolitinib and is weaning from sirolimus. The remaining 3 patients did not develop any form of GVHD and discontinued ISM at 20.7, 22.7, and 28.5 months post-transplant, respectively (16.8, 15.5, and 7.8 months after reinforced SC infusion, respectively). The reinforced SC infusion-free survival rates at 12 and 24 months were 83.9% (95% CI, 49.4–95.7) and 66.1% (95% CI, 32.5–85.8), respectively (Fig. 2). Five (71.4%) of 7 patients (1 patient is not eligible for weaning) who did not receive reinforced SC infusion were able to successfully discontinue sirolimus at a median 14.1 months (range, 3.9–18.4). All patients who received reinforced SC infusion achieved complete donor chimerism in terms of PB WB and donor T-cell with a median of 99.0% (95% CI, 93–100) while patients without the infusion all presented stable WB MC with a median of 89% (range, 79–97). In total, 8 patients (57.1%) discontinued ISM at the time of analysis (Fig. 1).

As a whole, the cumulative incidence of acute GVHD grade III–IV at day 100 after reinforced SC infusion was 20.0% (95% CI, 0–48.4). Two patients who received CD3+ cells at a dose above the median (26.3 × 107/kg) developed chronic GVHD. The cumulative incidences of severe chronic GVHD at 12 months was 20.0% (95% CI, 0.4–63.2). To date, none of these patients have experienced graft failure. No patients without reinforced SC infusion developed acute or chronic GVHD. Both CMV reactivation requiring pre-emptive therapy and hemorrhagic cystitis were observed in one patient (16.7%). Infectious complications of grade 3 were observed in one in terms of PB WB and donor T-cell with a median of 99.0%. Except for the above-described GVHD-related death, additional TRM was not observed.

Of the 3 patients with major ABO mismatches, 1 patient proceeded to the administration of reinforced SC infusion at 20.7 months post-transplant, achieved complete donor chimerism, and was weaned from ISM. Another patient discontinued ISM with a stable MC, not requiring reinforced SC infusion. The remaining patient has yet to reach 1 year post-transplant. Of the 3 patients with minor ABO mismatch, only 1 patient required reinforced SC infusion, while the remaining 2 patients successfully discontinued ISM without the need for infusion.

With a median follow-up duration of 31.5 months (range, 4.2 – 64.4), the OS and EFS at 4 years were 91.7% (95% CI, 53.9–98.8), respectively (Fig. 3a and 3b). The thalassemia-free survival rate in β-**TM** patients was 87.5% (95% CI, 38.7–98.1) at 4 years (Fig. 3c). The cumulative incidence of achieving PB donor T-cell chimerism >50% in patients not proceeding to reinforced SC infusion was 68.8% (95% CI, 4.5–89.8) at 4 years (Fig. 3d). Changes in donor chimerism after allo-SCT are shown in Fig. 4.

**4. DISCUSSION**

Unlike SCD patients, β-TM patients do not require chemotherapy nor is their immunological system impaired. Moreover, they have a robustly hyperplastic and expanded marrow compartment and allo-sensitization as a result of multiple transfusions [ref]. Therefore, the ideal conditioning for β-TM should be able to eradicate hyperplastic marrow and be sufficiently immunosuppressive to overcome the established allo-sensitization. Under these circumstances, alloSCT using MAC with busulfan and cyclophosphamide has been considered a standard regimen for β-TM patients receiving alloSCT [4]. However, MAC or even RIC is associated with higher TRM in adult β-TM patients who already have multiple comorbidities and advanced disease with marked erythroid expansion [ref]. Early experiences of alloSCT using MAC in adult β-TM patients showed poor outcomes, with an overall and rejection-free survival rates of only 65% and 62%, respectively [5]. The TRM was significant, ranging from 28% to 37%, depending on the dosage of cyclophosphamide [ref]. Accordingly, a safer conditioning regimen that can induce stable donor chimerism is required for this population.

Although there are several studies of alloSCT using NMA conditioning for adult SCD patients [2,6,7], it is currently very scarce for adult β-TM patients. By analogy with the behavior of malignant tissue, a large mass of rapidly proliferating hematopoietic tissue in β-TM is difficult to eradicate it and is more likely to recur after transplantation, with a low intensity conditioning. AlloSCT using NMA conditioning has been previously reported using a main population consisting of pediatric patients admixed with β-TM and SCD; the outcome was disappointing with only transient engraftment [1]. On the contrary, several studies support the observation that full donor chimerism for the clinical success of alloSCT is not mandatory in β-TM, as the persistence of even a small percentage of donor-derived erythropoiesis may maintain the potential to correct the phenotypic expression of the disease due to the competitive advantage of both donor-derived PB erythrocytes and erythroid progenitors over their β-TM counterparts . According to a long-term analysis, the occurrence of transient mixed chimerism does not necessarily lead to graft rejection and evolves, in most cases, toward complete donor chimerism or a status of stable persistent mixed chimerism [8]. In most reports, although the risk of rejection appears greatest in the first two months after transplantation, once persistent mixed chimerism is established, patients seem to be no longer exposed to the risk of GF, showing a stable functional graft without the need for additional red blood cell transfusion support [9]. Along with these data, a reliable achievement of stable mixed chimerism by alemtuzumab with low-dose TBI provides a rationale for alloSCT using NMA conditioning in β-TM patients. Indeed, a major population in our study was adult β-TM patients (9 of 13; 69.2%), of whom 7 (77.8%) achieved stable mixed chimerism for more than one year and 4 (30.8%) did not require additional optional reinforced SC infusion due to their PB donor T-cell chimerism being maintained at over 50% after one year. This result suggests that stable mixed chimerism could be induced in a significant portion of β-TM patients without requiring additional manipulations. Two of the three patients with optional reinforced SC infusion sustainably maintain a complete chimerism. To the best of our knowledge, our report is the first to show that alloSCT using NMA conditioning can be successfully applied to adult β-TM patients with achieving a stable mixed chimerism and correcting abnormal hemoglobin phenotypes.

One of themajor limitationsof the NIH protocol is the need for long-term immunosuppression in recipients with a persistently low donor T-cell chimerism (< 50%). Nearly half of the patients should have continued ISM with a median duration of 2.1 years [2]. Under this circumstance, sirolimus-related complications, especially secondary malignancies, become to be a major concern. Several reports found that a cumulative duration of immunosuppression over 24 months is associated with an increased incidence of secondary malignancies [10,11]. The secondary malignancy risk is especially problematic in patients who should take life-long sirolimus such as solid organ transplantation recipient [12,13]. Although no one developed a secondary malignancy in patients who received NIH protocol, the follow-up duration of the study was not long enough to determine its true incidence. In addition, sirolimus-related adverse drug reactions include anemia, thrombocytopenia, lipid metabolism disorder, new-onset diabetes mellitus, and hypertension and respiratory or urinary tract infections [14]. Protracted immunosuppression with sirolimus can be associated with increased morbidities from these reactions. The NIH protocol study, despite of long-term immunosuppression, found a graft rejection rate reached to approximately 13% [2]. Moreover, in a previous report analyzing the outcomes of secondary alloSCT for β-TM patients experiencing GF, their prognosis was extremely poor; nearly half of patients (14/29) died of regimen-related toxicities, chronic GVHD, and recurring GF after the secondary alloSCT. The EFS and OS at 3 years were only 58% and 68%, respectively [15].

We attempted to overcome these limitations using optional reinforced SC infusion after conditioning with 500 cGy TNI in cases of being unable to discontinue sirolimus after one year. At the time of the optional reinforced SC infusion, the median donor WB and T-cell chimerism were 35% and 23%, respectively. To date, no patient (including two patients with impending GF) experienced GF in our study. However, since there are several reports suggesting that a myeloid chimerism of around 20% is enough to achieve functional graft characterized by normal hemoglobin level, no need for red cell transfusion, no serum iron level increment and a limited degree of erythroid hyperplasia [9,16,17], careful attention should be paid in the selection of optimal candidates and cell dose infused when making decision on optional reinforced SC infusion due to the risk of GVHD. Notably, in a fatal case reported herein, the number of CD3+ cells infused was the highest among patients who received optional reinforced SC recipients, which can account for developing severe acute GVHD. Although no meaningful statistical conclusion can be drawn in our study due to the limited number of patients, the development of acute and chronic GVHD tended to be associated with the number of CD3+ cells infused, as expected.

Our study included a β-TM patient with experiencing delayed GF after previous alloSCT using MAC without radiation. After receiving alloSCT using our initial NMA conditioning, this patient discontinued sirolimus with stable mixed chimerism without an optional reinforced SC infusion, suggesting that a conditioning with alemtuzumab plus low-dose TBI may overcome graft loss after the intensive conditioning. A previous study reported that an increased dose of TBI substantially reduced GF with maintaining the safety of haploidentical alloSCT using NMA conditioning, indicating that irradiation a plays a significant role as a conditioning in this disease population [18].

The NIH protocol excluded major ABO-incompatible transplantation pairs. In alloSCT using MAC, ABO-incompatibility is generally known to being not a hurdle in achieving complete donor chimerism. However, in alloSCT using NMA conditioning, ABO mismatch can be responsible for GF, pure red cell aplasia and immune-mediated hemolysis [19-21]. Our study included three patients with major and minor ABO mismatches: one of them with major mismatch successfully withdrew from sirolimus without the need for optional reinforced SC infusion and has a stable mixed chimerism with a donor T-cell chimerism of 60%. Two of the three minor ABO mismatches did not require optional reinforced SC infusion and have currently discontinued sirolimus. These results suggest that ABO incompatibility is not associated with an increased incidence of GF and should not be regarded as a contraindication for alloSCT using NMA conditioning with alemtuzumab and low-dose TBI.

The fact that this study is retrospective and contained a small number of patients makes it difficult to draw concrete statistical conclusions from the results. Despite this limitation, our data shows some consistencies: inclusion of 13 consecutive patients, using uniform criteria for reinforced SC infusion, and uniform NMA conditioning. Additional limitations include the limited availability of suitable donors since the conditioning regimen could only be applied only to patients with HLA-matched related donors, as described previously [2]. This poses a major barrier for performing allo-SCT, as most patients with hemoglobin disorders do not have these donors [22]. Lastly, although our strategy was effective in preventing the patients from receiving long-term immunosuppression, there was on recorded fatality, as well as the possibility of developing of acute and chronic GVHD after reinforcedSC infusion. Since the number of CD3+ cells infused appears to be associated with these complications, further study will be needed to determine the optimal cell dose of the reinforced SC infusion to minimize the risk of GVHD while facilitating donor engraftment.

In conclusion, despite being retrospective and including a small number of patients, our study found that alloSCT using NMA conditioning of alemtuzumab plus low-dose TBI was effective in achieving stable mixed chimerism not only in SCD, but in β-TM patients. Our strategy of optional reinforced SC infusion was effective in preventing to continuing immunosuppression in patients. However, future studies are needed in order to determine the optimal cell dose in optional reinforced infusions.

**Acknowledgements**

We would like to thank all the house and nursing staff for their great work in the management of the patients.

**Competing interests**

The authors declare that they have no conflicts of interests.

**REFERENCES**

1. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia. *Biology of Blood and Marrow Transplantation.* 2003;9(8):519-528.

2. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. *JAMA.* 2014;312(1):48-56.

3. Jabbour E, Rondon G, Anderlini P, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. *Bone Marrow Transplant.* 2007;40(5):431-435.

4. Lucarelli G GM, Polchi P, Angelucci E, Baronciani D, Giardini C, Politi P, Durazzi SM, Muretto P, Albertini F. Bone Marrow Transplantation in Patients with Thalassemia. *New England Journal of Medicine.* 1990;322(7):417-421.

5. G. Lucarelli RC, M Galimbeti, E Angelucci, C Giardini, D Baronciani, P Polchi, M Andreani, D Gaziev, B Erer, A Ciaroni, FD'Adamo, F Albertini, P Muretto. Bone Marrow Transplantation in Adult Thalassemia Patients. *Blood.* 1999;93(4):1164-1167.

6. Saraf SL, Oh AL, Patel PR, et al. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. *Biol Blood Marrow Transplant.* 2016;22(3):441-448.

7. Wu CJ, Hochberg EP, Rogers SA, et al. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. *Experimental Hematology.* 2003;31(10):924-933.

8. M Andreani SN, G Lucarelli, P Tonucci, S Rapa, E Angelucci, B Persini, F Agostinelli, M Donati, M Manna. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. *Bone Marrow Transplantation.* 2000;25:401-404.

9. Andreani M, Testi M, Battarra M, et al. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. *Blood Transfusion.* 2008;6(3):143-149.

10. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. *Blood.* 2005;105(10):3802-3811.

11. Schmiegelow K, Levinsen MF, Attarbaschi A, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. *J Clin Oncol.* 2013;31(19):2469-2476.

12. Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. *Kidney Int.* 2004;66(1):383-389.

13. Rizvi SMH, Aagnes B, Holdaas H, et al. Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study. *JAMA Dermatol.* 2017;153(12):1270-1277.

14. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. *Transplant Rev (Orlando).* 2014;28(3):126-133.

15. Korula A, Pn N, Devasia A, et al. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen. *Biol Blood Marrow Transplant.* 2018;24(1):103-108.

16. Andreani M, Testi M, Battarra M, Lucarelli G. Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. *Chimerism.* 2011;2(1):21-22.

17. Andreani M, Testi M, Gaziev J, et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. *Haematologica.* 2011;96(1):128-133.

18. Bolaños-Meade J, Cooke KR, Gamper CJ, et al. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. *The Lancet Haematology.* 2019;6(4):e183-e193.

19. Wennerberg A, Backman KA, Gillerlain C, Robertson V, Jones C, Joyner T. Mixed erythrocyte chimerism: implications for tolerance of the donor immune system to recipient non-ABO system red cell antigens. *Bone Marrow Transplantation.* 1996;18(2):433-435.

20. AshrafBadros GT, Amir Toor, Christopher Morris, Chuanfa Guo, Nikhil Munshi, Bart Barlogie, Michele Cottler-Fox. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. *Transfusion.* 2002;18(2):433-435.

21. Helbig G, Stella-Holowiecka B, Wojnar J, et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. *Ann Hematol.* 2007;86(9):677-683.

22. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. *Blood.* 2011;118(5):1197-1207.

**Tables**

Table 1 Patients’ demographics and pre-transplant characteristics

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| UPN | Sex/Age | Diagnosis | Disease status | ECOG PS | HCT-CI | Donor → Recipient | |
| ABO compatibility | Sex compatibility |
| 01 | M/29 | β-thalassemia major | T/F dependency, Iron overloading | 1 | NA | NA | M → M |
| 02 | M/33 | β-thalassemia major | T/F dependency, Iron overloading | 1 | 4 | O+ → O+ | M → M |
| 03 | M/34 | β-thalassemia major | T/F dependency, Iron overloading | 1 | 5 | O+ → B+ | F → M |
| 04 | F/27 | Sickle cell β-thalassemia (homozygous HbSS), companying α-thalassemia silent carrier | T/F dependency, Recurrent sickle cell crisis | 1 | 0 | B+ → O+ | F → F |
| 05 | M/33 | Sickle cell anemia (homozygous HbSS type), companying α-thalassemia silent carrier | Recurrent sickle cell crisis, Regular Red cell exchange | 2 | 2 | B+ → B+ | M → M |
| 06 | F/26 | Sickle cell anemia (homozygous HbS/β type), companying α-thalassemia trait | Recurrent sickle cell crisis, Regular Red cell exchange | 1 | 2 | O+ → O+ | M → F |
| 07 | F/32 | β-thalassemia major, companying α-thalassemia trait | T/F dependency, Iron overloading | 1 | 2 | A+ → AB+ | M → F |
| 08 | F/31 | β- thalassemia major, companying α-thalassemia silent carrier | T/F dependency, Iron overloading | 1 | 3 | A+ → AB+ | F → F |
| 09 | F/24 | Sickle cell anemia | Previous APL (CR state), T/F dependency, Iron overloading | 1 | 3 | A+ → A+ | M → F |
| 10 | M/29 | β-thalassemia major | T/F dependency, Iron overloading | 2 | 2 | O+ → O+ | M → M |
| 11 | M/34 | β-thalassemia major, companying α-thalassemia silent carrier | T/F dependency, Iron overloading | 1 | 2 | B+ → B+ | F → M |
| 12 | F/25 | β-thalassemia major, companying α-thalassemia trait | Engraftment failure after MAC (Treosulfan + Cy) alloSCT, T/F dependency, Iron overloading | 1 | 2 | AB+ → B+ | M → F |
| 13 | F/34 | β-thalassemia major, companying α-thalassemia silent carrier | T/F dependency, Iron overloading | 1 | 2 | A+ → O+ | M → F |

Abbreviations: UPN, unique patient number; ECOG PS, Eastern Cooperative Oncology Group performance status; HCT-CI, Hematopoietic Cell Transplantation-specific Comorbidity Index; T/F, transfusion; Hb, hemoglobin; APL, acute promyelocytic leukemia; CR, complete remission; MAC, myeloablative conditioning; alloSCT, allogeneic stem cell transplantation; Cy, Cyclophosphamide

Table 2 Patients’ overall outcomes

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| UPN | Diagnosis | Cell dose of  1st stem cell infusion | | Cell dose of  2nd stem cell infusion | | Pre-transplant | Post-transplant outcomes | |
| CD34+  (× 106/kg) | CD3+  (× 107/kg) | CD34+  (× 106/kg) | CD3+  (× 107/kg) | Hb or HbS | Hb or HbS / Gene study / Chimerism, WB/T-cell (%) | GVHD / EFS/ OS |
| 01 | β-thalassemia major | 10.6 | NA | ND | | NA | Hb 13.0 g/dL @ 61.4 mo  c.92+5G>C (homozygous → heterozygous, donor type)  89/ 75@ 60.3 mo | No GVHD  EFS/OS@60.3 mo |
| 02 | β-thalassemia major | 10.5 | 28.3 | 13.0 | 27.9 | Hb 7.4 g/dLa | Hb 12.6 g/dL @ 54.3 mo  c.92+5G>C (homozygous → heterozygous, donor type)  99/100@ 46.6 mo | Severe cGVHD @ 2.5 mo after 2nd stem cell infusion  EFS/OS@50.2 mo |
| 03 | β-thalassemia major | 33.3 | 56.8 | 9.9 | 24.7 | Hb 7.8 g/dLa | Hb 13.7 g/dL @ 21.6 mo  c.92+5G>C (homozygous → not detected, donor type)  99/ 99@ 21.6 mo | No GVHD  EFS/OS@35.3 mo |
| 04 | Sickle cell β-thalassemia (homozygous HbSS), companying α-thalassemia silent carrier | 14.9 | 73.4 | 10.7 | 20.9 | HbS 70.8%b | HbS 30.6% @ 29.4 mo  c.20A>T (homozygous → heterozygous, donor type)  99/ 99@ 28.0 mo | Grade III aGVHD @ 0.2 mo after 2nd stem cell infusion  EFS/OS@33.5 mo |
| 05 | Sickle cell disease (homozygous HbSS type), companying α-thalassemia silent carrier | 12.8 | 15.8 | 14.4 | 16.3 | HbS 64.5%b | HbS 34.5% @ 22.7 mo  c.20A>T (homozygous → heterozygous, donor type)  99/ 99@ 27.0 mo | No GVHD  EFS/OS@31.6 mo |
| 06 | Sickle cell disease (homozygous HbS/β type), companying α-thalassemia trait | 17.8 | 55.0 | ND | | HbS 89.3% b | HbS 40.3% @ 21.9 mo  c.20A>T, C92+1G>A (homozygous → heterozygous, donor type), 79/33@ 27.0 mo | No GVHD  EFS/OS@23.2 mo |
| 07 | β-thalassemia major, companying α-thalassemia trait | 8.8 | 39.9 | ND | | Hb 7.6 g/dLa | Hg 15.4 g/dL @ 18.7 mo  c.92+5G>C (homozygous → heterozygous, donor type)  85/64@ 18.7 mo | No GVHD  EFS/OS@21.1 mo |
| 08 | β- thalassemia major, companying α-thalassemia silent carrier | 10.6 | 77.3 | ND | | Hb 7.6 g/dLa | Hb 14.4 g/dL @ 18.0 mo  c.92+5G>C (homozygous → not detected, donor type)  95/74@ 18.7 mo | No GVHD  EFS/OS@20.4 mo |
| 09 | Sickle cell disease | 23.0 | 56.8 | ND | | HbS 75.1% b | HbS 40.3% @ 23.3 mo  c.20A>T (homozygous → heterozygous, donor type)  86/73@ 21.9 mo | No GVHD  EFS/OS@19.2 mo |
| 10 | β-thalassemia major | 16.0 | 52.4 | ND | | Hb 7.7 g/dLa | Hb 12.5 g/dL @ 7.3 mo  c.92+5G>C (homozygous → heterozygous, donor type)  97/34@ 6.9 mo | No GVHD  EFS/OS@18.7 mo |
| 11 | β-thalassemia major, companying α-thalassemia silent carrier | 14.3 | 55.2 | 8.5 / 52.9 | | Hb 9.2 g/dLa | Hb 6.2 g/dL @ 16.5 mo  c.92+5G>C (homozygous → heterozygous, donor type)  86/ 93@15.5 mo | EFS/EFS@16.5 mo  Grade III aGVHD @ 0.4 mo after 2nd stem cell infusion |
| 13 | β-thalassemia major, companying α-thalassemia trait | 17.1 | 56.8 | ND | | Hb 6.6 g/dLa | Hb 14.1 g/dL @ 14.7 month  C.93-22\_95del (homozygous → heterozygous, donor type), 89/ 46@ 13.0 mo | No GVHD  EFS/OS@13.1 mo |
| 14 | β-thalassemia major | 14.6 | 49.4 | ND | | Hg 7.8 g/dLa | Hg 11.0 g/dL @ 4.2 month  c.92+5G>C (homozygous → heterozygous, donor type)  96/46 @ 2.2 mo | No GVHD  EFS/OS@4.2 mo |

*UPN* unique patient number *Hb* Hemoglobin *GVHD* Graft-versus-host disease *EFS* event-free survival *OS* overall survival *NA* not available *ND* not done *WB* whole blood *aGVHD* acute graft-versus-host disease *cGVHD* chronic graft-versus-host disease *Ig* immunoglobulin.

a To avoid influences by packed red cell transfusions, the lowest Hg levels of β-thalassemia major patients during pre-transplant 3 months were presented.

b Hemoglobin S level and serum immunoglobulin level of sickle cell anemia or hypogammaglobulinemia just before transplantation were showed.

**Figure Legends**

Fig. 1 Overall outcomes of 13 patients who received transplantation according to our strategy.

Fig. 2 Proportion of reinforced stem cells infusion-free survival.

Fig. 3 Survival outcomes. (a) Overall survival, (b) event-free survival, (c) thalassemia-free survival, (d) incidence of PB T-cell chimerism > 50%

Fig. 4 Changes in donor chimerism. (a) PB T-cell chimerism of the patients receiving reinforced stem cells infusion, (b) PB whole-cell chimerism of the patients receiving reinforced stem cells infusion, (c) PB T-cell chimerism of the patients not receiving reinforced stem cells infusion, (d) PB whole-cell chimerism of the patients not receiving reinforced stem cells infusion. Black dot indicates reinforced stem cell infusion.